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Africa and Smith Journal of Negative Results in BioMedicine  (2015) 14:14 
DOI 10.1186/s12952-015-0031-yRESEARCH Open AccessSutherlandia frutescens may exacerbate
HIV-associated neuroinflammation
Luan Dane Africa and Carine Smith*Abstract
Background: Neuroinflammation is central to the aetiology of HIV-associated neurocognitive disorders (HAND) that
are prevalent in late stage AIDS. Anti-retroviral (ARV) treatments are rolled out relatively late in the context of
neuroinflammatory changes, so that their usefulness in directly preventing HAND is probably limited. It is common
practice for HIV+ individuals in developing countries to make use of traditional medicines. One such medicine is
Sutherlandia frutescens - commonly consumed as a water infusion. Here its efficacy as an anti-inflammatory modality
in this context was investigated in an in vitro co-culture model of the blood–brain barrier (BBB).
Methods: Single cultures of human astrocytes (HA), HUVECs and primary human monocytes, as well as co-cultures
(BBB), were stimulated with HIV-1 subtype B & C Tat protein and/or HL2/3 cell secretory proteins after pre-treatment
with S.frutescens extract. Effects of this pre-treatment on pro-inflammatory cytokine secretion and monocyte migration
across the BBB were assessed.
Results: In accordance with others, B Tat was more pro-inflammatory than C Tat, validating our model. S.frutescens
decreased IL-1β secretion significantly (P < 0.0001), but exacerbated both monocyte chemoattractant protein-1
(P < 0001) – a major role player in HIV-associated neuroinflammation – and CD14+ monocyte infiltration across
the BBB (P < 0.01).
Conclusions: Current data illustrates that the combined use of HL2/3 cells and the simulated BBB presents an
accurate, physiologically relevant in vitro model with which to study neuroinflammation in the context of HIV/AIDS. In
addition, our results caution against the use of S.frutescens as anti-inflammatory modality at any stage post-HIV infection.Introduction
Neuroinflammation in the context of HIV/AIDS is
known to have onset soon after infection with the virus
and is associated with the HIV-associated neurocognitive
disorders (HAND) that are prevalent in late stage AIDS
[1]. Conventional anti-retroviral treatments are rolled
out relatively late in the context of neuroinflammatory
changes, so that their usefulness in directly preventing
HAND is probably limited. A recent multi-centre study
in more than 800 HIV+ patients [2], reported that high
rates of neurocognitive impairment persist at all stages
of HIV infection, despite modern anti-retroviral treat-
ment and immune reconstitution regimes. Furthermore,
in the same study, neurocognitive impairment was con-
sistently associated with lowest CD4 counts. From this,
it is clear that early prevention strategies to limit the* Correspondence: csmith@sun.ac.za
Department of Physiological Sciences, Stellenbosch University, Private Bag
X1, Matieland 7602, South Africa
© 2015 Africa and Smith. This is an Open Acc
License (http://creativecommons.org/licenses/
medium, provided the original work is proper
creativecommons.org/publicdomain/zero/1.0/extent of neuroinflammation, is required to positively in-
fluence the longer-term prognosis in terms of not only
HAND, but also disease progression.
Traditional medicine is commonly used by those living
with HIV infection, particularly in developing countries.
One such complementary medicine that is widely used,
is Sutherlandia frutescens (Fabaceae alt. Leguminosae,
Goldblatt & Manning 1812) – a herb that is commonly
consumed in the form of a tea. Several beneficial effects
relevant to HIV/AIDS have been reported for this herbal
remedy. Firstly, it was shown to directly inhibit activity
of HIV-target enzymes [3]. Secondly, the use of S. frutes-
cens has been associated with benefits in the peripheral
compartment - decreased psychological stress levels [4, 5]
and preservation of skeletal muscle mass [6] suggests a
less catabolic state and maintenance of overall body
strength. Thirdly, central uptake and effect was reportedess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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convulsant [8] effects of S. frutescens via modulation of
GABAergic neurotransmission.
As a result of these promising data, the use of S. fru-
tescens in the context of HIV/AIDS is currently en-
dorsed by the Ministries of Health of several African
nations [9]. Even though S. frutescens was recently im-
plicated in herb-drug interactions which may lead to
therapeutic failure and/or increased drug toxicity in the
context of HIV anti-retrovirals specifically [10–13]
clinic staff continue to recommend its use to HIV+ pa-
tients still waiting for ARV roll out, for management of
secondary symptoms of HIV/AIDS in otherwise un-
treated patients (personal communications to CS).
From the literature reviewed, S frutescens is known to
be absorbed and have central activity, but its potential
role in modulation of neuroinflammation has not been
assessed. This fact, together with the fact that it is cur-
rently being used widely in the time frame of disease
progression where treatments for neuroinflammation
should be applied, warrants investigation into the poten-
tial of S. frutescens as anti-inflammatory modality in the
context of HIV-associated neuroinflammation. Therefore,
the effect of S. frutescens treatment on monocyte migra-
tion across a simulated blood–brain barrier was assessed
in vitro. In addition, effects on the secretion of inflamma-
tory modulators by various cell types were investigated.
Materials and methods
Cell culture
Single cultures of primary human cerebrocortical astro-
cytes (HA) (Sciencell, USA) and Human Umbilical Vein
Endothelial Cells (HUVECs) (Lonza, Germany) were
maintained at 37 °C in a humidified 5 % CO2 in high
glucose DMEM (Life Technologies Corp., USA) supple-
mented with 10 % FCS (Biochrom, Germany) and
1 % N2 Supplement (Life Technologies Corp., USA) and
complete EGM (Lonza, Germany) respectfully. HL2/3
cells (obtained through the NIH AIDS Reagent Program,
Division of AIDS, NIAID, NIH: HL2/3 from Dr. Barbara K.
Felber and Dr. George N. Pavlakis), HeLa derived cells pro-
ducing high levels of Gag, Env, Tat, Rev and Nef proteins,
were maintained at the conditions mentioned above in
high glucose DMEM (Life Technologies Corp., USA) sup-
plemented with 10 % FCS (Biochrom, Germany). Cells
were routinely sub-cultured before reaching confluence.
Cell numbers were determined using a haemocytom-
eter following trypsinization and trypan blue staining.
For 3-[4,5- dimethylthiazol-2-yl]-2,5-diphenyl tetrazo-
lium bromide (MTT) assays, HA and HUVECs were
seeded in 6 well cell culture plates (500000 cells/well).
For all other single culture experiments all cell types
were seeded in 6 well cell culture dishes at the afore-
mentioned cell density.In order to simulate the blood–brain barrier, co-
cultures of HA and HUVECs were established on oppos-
ite sides of fibronectin (BD Biosciences, USA) coated
3 μm pore size tissue culture inserts (BD Biosciences,
USA) [14].
All cell culture experiments were done in triplicate
and repeated a minimum of three times.
Preparation of S. frutescens aqueous extract
Commercially available plant material was kindly do-
nated by Mr Ulrich Feiter (Parceval Pharmaceuticals Pty
Ltd). Sutherlandia frutescens plants were cultivated from
commercial stock seed which have been previously taxo-
nomically verified as S. frutescens var. SU1 (registered
product code 02P0058), harvested (well after flowering
and seeding phase) and dry milled (leaves and stems
only) by Parceval Pharmaceuticals Pty Ltd (Wellington,
South Africa) using proprietary procedures. A warm
water extract of dry-milled S. frutescens (moisture con-
tent 16.41 %) was prepared in boiling distilled water
(25 mg/ml) using methods previously described for
in vivo treatment [4, 7] and then sterile filtered using fil-
ter pore size 0.22 μm.
S. frutescens dose response cell viability assay
In order to determine the highest dose of S. frutescens
tolerated with the least amount of cell death, human as-
trocytes, HUVECs and primary human monocytes were
incubated with 50, 500 and 5000 μg/ml S. frutescens ex-
tract for 24 h.
Cell viability was assessed using a modified version of
the MTT assay described by Gomez and colleagues [15].
The assay is based upon the principle of reduction of
MTT into blue formazan pigments by viable mitochon-
dria in healthy cells. At the end of the experiment, the
medium was removed from the 6 well plates and the
cells washed twice with PBS. MTT (0.01 g/ml) was dis-
solved in PBS, and 500 μl was added to each well dish.
Cells were subsequently incubated for 1 h at 37 °C in an
atmosphere of 5 % CO2. After the incubation period,
cells were washed twice with PBS, and one ml of HCl–
isopropanol–Triton (1 % HCl in isopropanol; 0.1 %
Triton X- 100; 50:1) was added to each well and gently
agitated for 5 min. This lysed the cell membranes and
liberated the formazan pigments. The suspension was
then centrifuged at 131 × g for 2 min. The optical
density (OD) was determined spectrophotometrically
at a wavelength of 540 nm and the values expressed as
percentages of control.
Full length HIV-1 subtype B & C Tat protein stimulation
Full length synthetic Tat proteins were kindly provided
by Professor Ranga Udaykumar of the Jawaharlal Nehru
Centre for Advanced Scientific Research (Bangalore,
Africa and Smith Journal of Negative Results in BioMedicine  (2015) 14:14 Page 3 of 9India) and were synthesized and purified as previously
described [16]. Tat proteins were reconstituted and sub-
sequently diluted in Tris-Cl buffer (20 mM, pH8) sup-
plemented with 1 mM DTT.
Human astrocytes, HUVECs, primary human mono-
cytes as well as simulated BBB co-cultures were stimu-
lated with either protein (10 ng/ml) for 2.5 h and 24 h,
after which culture media was collected and stored at
−80 °C for subsequent analyses. In order to test the effi-
cacy of S. frutescens as a modulator of neuroinflamma-
tory processes, cells were pre-treated for 4 h and 24 h
respectively prior to HIV-1 Tat protein stimulation. Fol-
lowing stimulation culture supernatants were collected
and stored at −80 °C until further analysis.HL2/3 Cells – A more representative in vitro model of
HIV-1 infection
As previously mentioned, HL2/3 cells produce and se-
crete high levels of most HIV-1 subtype B proteins into
their culture media, and for this reason it was decided to
co-culture these cells with the simulated BBB cultures in
order to mimic the neuroinflammatory milieu at the
interface between the infected central nervous system
(represented by the HL2/3 cells seeded into the wells of
a 24 well culture plate into which the tissue culture in-
serts, on which the simulated BBB has been constructed,
are placed) and the neurovasculature (i.e., the BBB rep-
resented by the in vitro simulated BBB cultures). Firstly,
to assess the effect of the HL2/3 derived HIV-1 proteins
on the individual cell types used to construct the in vitro
BBB, HL2/3 cells were seeded into 6 well plates at 200
000 cells per well and allowed to adhere to the culture
surface. Once the HL2/3 cells had adhered, culture
media was replaced. HL2/3 conditioned media was col-
lected at 2.5 h and 24 h from separate cultures, and this
media was then used to stimulate human astrocytes,
HUVECs and primary human monocytes for either 2.5 h
or 24 h. Also, as in the aforementioned section outlining
the HIV-1 Tat experiments, cells were pre-treated with
S. frutescens for either 4 h or 24 h prior to stimulation.
Culture supernatants were collected post stimulation
and stored at −80 °C until further analysis.
The aforementioned experiment was repeated in the
co-culture system, with the omission of the 24 h time
point. HL2/3 cells were seeded into 24 well plates at 50
000 cells/well and allowed to adhere. Culture media was
refreshed after which the BBB co-cultures were trans-
ferred to the wells containing the HL2/3 cells. BBB co-
cultures were exposed to the HL2/3 cells for a period of
2.5 h, after which culture supernatants were collected
and stored at −80 °C for further downstream analyses.
Additional BBB co-cultures were treated with S. frutescens
for 4 h prior to stimulation.Pro-inflammatory cytokine & chemokine analysis
Monocyte chemoattractant protein-1 (MCP-1), a key
role player in HIV-1-associated neuroinflammation, was
measured in all supernatants by a conventional ELISA
kit (Biolegend, San Diego, CA), used according to the
manufacturer’s instructions.
IL-1β was measured in all co-culture supernatants by
AlphaLISA (PerkinElmer, Waltham, MA), according to
the manufacturer’s instructions.
Monocyte/macrophage transmigration
Transmigration of both infected and uninfected inflam-
matory cells, in particular those from the monocyte
macrophage lineage, play a major role in the aetiology of
HIV-1-associated neuroinflammation. For this reason
monocyte transmigration was assessed in the BBB co-
cultures by adding primary human monocytes to the top
of the insert, allowing the cells to migrate in response to
the various stimuli for 2.5 h, after which the BBB inserts
and cells in the bottom of the well were fixed in 4 %
paraformaldehyde and stained with a FITC-anti-human
CD14 antibody (Biolegend, San Diego, CA). CD14 is a
specific marker of cells from the monocyte/macrophage
lineage. All CD14+ monocytes on top of the entire in-
sert (unmigrated) and on the bottom of the culture well
(migrated) were counted using a fluorescent micro-
scope (Leica, Germany). Cells in suspension were not
quantified, since we have previously shown that cell
counts in these compartments are independent of inter-
ventions/treatments [17].
Statistical analysis
All statistical analyses were performed using Graphpad
Prism Version 5 software (Graphpad Software, La Jolla,
CA, USA). Results are expressed as mean ± SD. One- or
two- way analysis of variance (ANOVA) as relevant,
followed by a Bonferroni post hoc test, was used to as-
sess differences between experimental groups and/or
time points. Differences were considered to be of statis-
tical significance when P value ≤ 0.05.
Results
Due to the fact that S. frutescens had not, up until this
point, been tested on the cell types used in this study, it
was important to first establish the optimal dose for use
in vitro, prior to assessment of S. frutescens as an effect-
ive anti-inflammatory modality. We defined this optimal
experimental dose as the highest dosage which does not
result in a significant reduction in cell viability, repre-
sented by % MTT reductive capacity, Across all three
cell types, a marked, statistically significant reduction in
% MTT reductive capacity was observed in the group
treated with 5000 μg/ml S. frutescens at all time points
(P < 0.0001 when compared to control; refer to Additional
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significant changes in cell viability were observed for any
of the other treatment doses at any time point, and thus
the highest of these - 500 μg/ml - was selected as the opti-
mal experimental dose.
MCP-1 responses were evaluated in human astrocytes,
HUVEC, primary human monocyte and BBB co-cultures
following stimulation with HIV-1 subtype B & C Tat
protein, and also HL2/3 conditioned media in the case
of astrocytes, HUVECs and monocytes, and co-culturing
BBB cultures with HL2/3 cells. The potential of S. frutes-
cens as a modulator of inflammation was evaluated by
pre-treating cells with S. frutescens prior to introduction
of the inflammatory stimulus.
In the absence of HIV-associated proteins, control as-
trocytes secreted low basal levels of MCP-1 at 6.5 h, but
no MCP-1 was detectable after 24 h in culture (Fig. 1a).
After exposure to either B Tat or HL2/3 cell products,
MCP-1 secretion increased significantly over time up to
the 24 h point (all P < 0.0001 when compared to con-
trol). As expected, C Tat elicited no MCP-1 response.Fig. 1 MCP-1 response to HIV-1 proteins in human astrocytes (a), HUVECs (
extract. SU1 indicates groups pre-treated with S. frutescens. SU 1 pre-treatmen
24 h experiments. Results are expressed as mean ± SD. *** = P < 0.0001; ** = PPre-treatment with S. frutescens in absence of HIV pro-
teins seemed to reduce basal secretion of MCP-1. How-
ever, it exacerbated the response to both B Tat and HL2/
3 cell products in stimulated cells at both 6.5 and 24 h
(all P < 0.0001 when compared to control).
In HUVECs (Fig. 1b), basal MCP-1 secretion followed
a similar pattern to that seen in astrocytes at 6.5 h, with
the exception of C Tat, which also elicited a basal re-
sponse in this cell type (P < 0.0001 when compared to
control). In contrast to astrocytes, this basal secretion
was maintained and even relatively enhanced at 24 h. In
the absence of HIV proteins, HUVECs responded simi-
larly to astrocytes when S. frutescens pre-treated, show-
ing smaller increases in basal MCP-1 levels. In the
presence of all HIV protein stimuli employed, MCP-1
secretion increased continuously up to 24 h. Although S.
frutescens did not exacerbate the response in this cell
type, the S. frutescens-associated inhibition of the MCP-
1 response seen in non-HIV conditions, was insufficient
to restore the response after exposure to HIV proteins at
24 h to control levels.b) and BBB co-cultures (c), with or without pre-treatment with S.frutescens
t duration was 4 h for the 6,5 h experiments, and 24 h in the case of the
< 0.001
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culture simulation of the BBB (consisting of astrocytes,
HUVECs and monocytes, Fig. 1c), the net effect of S.
frutescens that may be expected in an in vivo situation
becomes more evident. Pre-treatment with S. frutescens
had no beneficial effect on the HIV Tat (both B and C)
associated MCP-1 response and exacerbated the HL2/3-
induced response (P < 0.0001). (Monocyte cultures did
not secrete detectable levels of MCP-1 under any of the
experimental conditions, so most probably did not con-
tribute significantly to this outcome.) These results sug-
gested that HIV Tat proteins are not a therapeutic target
of S. frutescens. Also, treatment with HL2/3 conditioned
media or co-culture with these cells (which contain Tat
as well as other HIV proteins) resulted in the most pro-
nounced inflammatory response. Therefore, HL2/3 cells
were selected as pro-inflammatory stimulus for all fur-
ther experiments. Additionally, the fact that these cells
secrete a greater repertoire of HIV-1 proteins makes
them a more physiologically representative model of
infection.
IL-1β levels were non-detectable in single cultures of
HL2/3 cells (data not shown), so that any IL-1β detected
originated from the BBB. IL-1β secretion was evaluated
in BBB cultures stimulated by co-culture with HL2/3
cells. Pre-treatment of the BBB cultures with S. frutes-
cens was able to effectively inhibit the IL-1β response
following co-culture with HL2/3 cells, so that the re-
sponse was similar to basal secretion levels (Fig. 2).Fig. 2 IL-1β response to co-culture exposure of BBB co-cultures to HL2/3 c
groups pre-treated with S. frutescens for 4 h. Results are expressed as meanMigration of primary human monocytes across the
BBB was assessed, as well as the role of S.frutescens as
modulator of this process. The number of monocytes
remaining on top of the transwell filter insert (contain-
ing BBB) was named unmigrated cells, while those col-
lecting in the bottom of the well are referred to as the
migrated cells. Representative images of immunocyto-
chemistry used to visualise monocytes for the purpose of
quantification, are presented in Fig. 3 and illustrate the
marked differences in CD14+ monocyte counts between
the experimental groups. Numerical data are presented
in Fig. 4. As anticipated, HL2/3 stimulation resulted in a
significant increase in monocyte migration across the
in vitro BBB (ANOVA main effect P < 0.0001). Pre-
treatment with S. frutescens had no effect on migration
in absence of HIV proteins, but exacerbated the mono-
cyte migration capacity in response to HL2/3 stimulation
significantly.
Discussion
Neuroinflammation is central to the aetiology, progres-
sion and prognosis of neurocognitive disorders associ-
ated with HIV infection. In addressing this problem, it is
of paramount importance to not only search for poten-
tial therapeutic modalities, but also to invest in develop-
ment of the best investigative models with which to
evaluate these potential therapies. We believe that our
data, presented here, contribute significantly to the ad-
vancement on both these fronts. Firstly, a novel aspectells, in the presence or absence of S.frutescens extract. SU1 indicates
± SD. *** = P < 0.0001; ** = P < 0.001
Fig. 3 Representative images indicating the effect of S.frutescens extract on migration capacity of CD14+ (FITC) primary human monocytes across
a simulated BBB. Magnification: 40× objective. SU1 indicates groups pre-treated for 4 h with S. frutescens
Fig. 4 Effects of 4 h of S.frutescens extract pre-treatment on monocyte migration across an in vitro BBB. SU1 indicates groups pre-treated with S.
frutescens. Results are expressed as mean ± SD. *** = P < 0.0001; ** = P < 0.001
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more physiologically relevant manner than other non-
infectious methods commonly employed, conditions fol-
lowing HIV 1 subtype B infection. Furthermore, to our
knowledge no other group has employed this model to
test the efficacy of a complimentary medicine that is cur-
rently recommended for use in a HIV population at risk
of neuroinflammation.
In terms of the model, HL2/3 cells are mostly used in
research focused on studying viral fusion mechanisms
[18]. Here, we have used this cell type in a novel applica-
tion, utilising its high-level production of a variety of
HIV-associated proteins, including Gag, Env, Tat, Rev
and Nef, to stimulate neuroinflammation in vitro. The
simulated BBB co-culture, originally used for testing
chemokine and monocyte migration responses to HIV-1,
[19] was used here in a broader application to investigate
efficacy of a natural extract. Proof of the accuracy of the
model is the fact that data generated from the HIV-1
subtype B & C Tat stimulation experiments – showing
that subtype B is more inflammatory than subtype C –
are congruent with previous reports in the literature
[20]. The combined use of the BBB model and HL2/3
cells substantially improved the outcome of our investi-
gation. For example, results suggesting that S. frutescens
aggravates the MCP-1 response independent of Tat, may
have been missed using stimulation with single proteins
alone. We confidently recommend the use of this model
to evaluate modulatory effects of various compounds/
drugs/medicines which may have the potential toFig. 5 Schematic representation of inflammatory signalling pathways assoc
current data is indicated with a green star. Abbreviations: Mitogen activated p
c-Jun N-terminal Kinase (JNK); Early Growth Response protein-1 (Egr-1); NLRP3modulate HIV-1 induced inflammatory processes within
and surrounding the neurovasculature.
Turning our attention to the complementary medicine
evaluated, at first glance results may seem contradictory,
with both HIV protein-stimulated MCP-1 production
and monocyte migration suggesting a pro-inflammatory
effect of S.frutescens, while the decreased IL-1β levels
after pre-treatment seems to argue against this inter-
pretation. However, these results may be explained by
delineating the signalling pathways involved in pro-
inflammatory cytokine production, which are affected
by the plant. A simplified signalling pathway is pre-
sented in Fig. 5, illustrating three main avenues by
which the production of MCP-1 and IL-1β are affected.
HIV-1 and its associated proteins set off an inflamma-
tory cascade, activating all three these signal transduc-
tion pathways, one via direct activation of the NLRP3
inflammasome, [21] and the other two by activation of
either of ERK1/2 or JNK [22]. S. frutescens has been the
subject of research for a number of years due to its
claimed effectiveness against cancer, stress and cachexia
– this research elucidated some signalling targets of the
plant relevant to the current study. For example, S. fru-
tescens has been reported to inhibit activation of ERK1/2
[23, 24] and p38 MAPK [6], albeit in non-HIV models.
In the context of our data, inhibition of ERK1/2-activation
of the Egr-1 and p38MAPK pathways did not eliminate
signalling to achieve MCP-1 production, which was in-
creased in the presence of HIV proteins, and even further
after S. frutescens pre-treatment, suggesting a relative up-iated with HIV-1 infection. Novel mechanism of action elucidated by
rotein kinase (MAPK); Extracellular signal-regulated kinase 1/2(ERK1/2);
– NOD-like receptor family, pyrine domain containing 3
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cumulative manner by HIV proteins and S. frutescens.
This up-regulation of JNK after HIV infection has been
reported previously in the context of HIV-associated
neurocognitive disorders, where it was associated with
up-regulation of AP-1-mediated increases in pro-
inflammatory cytokines IL-6 and IL-8 [25]. However,
our finding that S. frutescens exacerbated this neuroin-
flammatory response is novel.
Additionally, the phosphorylation of the transcription
factor AP-1 is known to enhance its transcriptional con-
trol of genes involved in the inflammatory process, in
this case MCP-1. The 5’-flanking region of the MCP-1
gene contains multiples AP-1 binding sites [26], thus in-
creased flux through the JNK pathways would naturally
lead to increased MCP-1 gene expression and conse-
quent protein translation. The fact that this JNK-
mediated up-regulated MCP-1 response did not translate
to increased IL-1β levels – as in fact it did in the pres-
ence of HIV proteins – suggests that S. frutescens may
also inhibit the NLRP3 inflammasome, which is the
predominant pathway responsible for conversion of
pro-IL-1β to IL-1β by caspase-1 (also called IL-1 con-
verting enzyme) [27]. The latter may also explain the
anti-inflammatory function of S. frutescens reported
here under non-HIV basal conditions (when JNK is
usually not activated and ERK activity predominates to
deliver a flux of relatively smaller magnitude). This sug-
gests that while S. frutescens may well have an anti-
inflammatory effect which is potentially useful under
basal conditions, the opposite is true in the presence of
HIV proteins: under these conditions, JNK-activated
pro-inflammatory pathways predominate and are fur-
ther enhanced by S. frutescens. This effectively over-
comes the previously reported S. frutescens-induced
inhibition of similar pro-inflammatory pathways which
do not predominate under these conditions, effectively
resulting in a net pro-inflammatory outcome, as sup-
ported by our result of an increase of inflammatory
leukocyte migration across the simulated BBB. This up-
regulation of JNK in an HIV model suggests a new tar-
get for S. frutescens which has not yet been elucidated.
Extrapolating our data to a clinical application, CNS
infiltration of both HIV-1 infected and uninfected
monocytes is one of the main routes by which the virus
enters and seeds the CNS as a viral reservoir to initiate
neuroinflammatory processes. Thus, in order for any
anti-inflammatory modality to be useful in this context,
it would need to modulate this response – as we have
previously demonstrated for grape seed-derived polyphe-
nols [28] – which S. frutescens does not, and which it in
fact seems to aggravate. Thus, in our opinion the use of
S. frutescens should be avoided in the presence of HIV
infection, as our data suggests that S. frutescens mayincrease monocyte infiltration into the CNS of HIV pa-
tients. Staying with clinical application, a recent study by
Fasinu et al. [10] has also cautioned the use of S. frutes-
cens by HIV+ patients on ARVs, due to the fact that the
herb is able to inhibit enzymes involved in the metabolic
clearance of these drugs. Given this data, the use of S.
frutescens as complimentary medicine to patients already
on ARV has been discouraged. However, use of medi-
cinal plants by HIV-patients waiting for roll-out, is cur-
rently recommended by the Ministries of Health in
several African countries – in South Africa, S. frutescens
is recommended in this context [9] for prevention of
cachexia, a beneficial effect of the plant previously re-
ported by our group, as well as to prevent neuroinflam-
matory changes which were recently reported to occur
in the early phases after infection, i.e., prior to ARV roll-
out [1]. However, no data supports the latter application
and our data now suggests that S. frutescens may in fact
promote development of neurocognitive disorders by ex-
acerbating inflammation and not inhibiting it in the con-
text of neuroinflammation specifically. We urge policy
makers to incorporate this evidence in their education of
this at risk population as well as the health care practi-
tioners providing primary care to them.
Conclusions
In conclusion, current data illustrates that the combined
use of HL2/3 cells and the simulated BBB presents an
accurate, physiologically relevant in vitro model with
which to study neuroinflammation in the context of
HIV/AIDS. In addition, our results caution against the
use of S. frutescens as anti-inflammatory modality at any
stage post-HIV infection.
Additional file
Additional file 1: Cell viability over time after exposure to Sutherlandia
frutescens extract. Human astrocyte (HA), human umbilical vein
endothelial cell (HUVEC) and primary human monocyte cultures were
exposed to Sutherlandia frutescens extract (50, 500 and 5000 ug/ml) for
up to 24 h, before viability was assessed using the MTT assay. From
these data, the 500 ug/ml dose of S. frutescens was chosen for all
experimental work, as described also in the methods section.
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